Table 2 Comparison of characteristics of patients in short-term (ST) group at baseline and after 6 months of withdrawal
Baseline | After 6 months | p | |
|---|---|---|---|
Body weight (kg) | 92 (75.5–107.3) 93.9 ± 23.7 | 96 (76–116) 98 ± 25.3 | 0.019 |
BMI (kg/m2) | 32.7 (26.9–34.7) 33.7 ± 9.5 | 33.3 (26.6–39.7) 35.2 ± 10.2 | 0.023 |
Waist circumference (cm) | 106.5 (92–119.8) | 107 (89.5–118.5) | 0.722 |
Systolic blood pressure (mmHg) | 124.5 (113.8–130) | 123 (113.5–137.5) | 0.688 |
Diastolic blood pressure (mmHg) | 84.5 (80–98.5) | 84 (80–103.5) | 0.118 |
No. of menstrual bleeding in last 6 month | 6 (4.3–6) | 6 (4.5–6) | 0.715 |
TFEQ-R18: cognitive restraint (%) | 61.1 (50.0–66.7) | 61.1 (45.8–84.7) | 0.682 |
TFEQ-R18: emotional eating (%) | 22.2 (0.0–77.8) | 22.2 (13.9–52.8) | 0.319 |
TFEQ-R18: uncontrolled eating (%) | 22.2 (3.7–40.7) | 33.3 (10.2–40.7) | 0.034 |
Total cholesterol (nmol/L) | 4.7 (3.3–5.5) | 4.6 (3.1–6.1) | 0.562 |
HDL (mmol/L) | 1.4 (1.1–1.5) | 1.4 (1.1–1.7) | 0.474 |
LDL (mmol/L) | 2.4 (1.6–3.5) | 2.1 (1.6–3.6) | 0.858 |
TG (mmol/L) | 1.2 (0.8–1.7) | 1.4 (0.8–2) | 0.723 |
FSH (IU/L) | 4.7 (2.9–6.4) | 5.2 (3.3–6.2) | 1.000 |
LH (IU/L) | 7.7 (5.4–9.5) | 9.5 (5.3–16.2) | 0.328 |
SHBG (nmol/L) | 31.8 (22–68.2) | 32.6 (20.4–75.7) | 0.552 |
Total testosterone (nmol/L) | 1.02 (0.69–1.58) | 0.83 (0.69–1.5) | 0.110 |
FAI score (%) | 3 (2–4) | 3 (1–4) | 0.473 |
Free testosterone (pmol/L) | 6.5 (5.9–8.4) | 5.8 (4.9–7.2) | 0.382 |
Androstenedione (nmol/L) | 5.4 (4.3–7) | 6.8 (4.6–9.9) | 0.075 |
Glucose OGTT 0 (mmol/L) | 5.3 (4.9–5.6) | 4.9 (4.5–5.5) | 0.021 |
Glucose OGTT 120 (mmol/L) | 5.8 (5.1–8.1) | 5.5 (4.2–7.3) | 0.506 |
Insulin OGTT 0 (mU/L) | 0.7 (0.6–1.3) | 0.8 (0.5–1.4) | 0.239 |
Insulin OGTT 120 (mU/L) | 69 (42.3–124.3) | 66.5 (37.2–174.5) | 0.249 |
HOMA-IR score | 2.5 (1.4–4.9) | 1.7 (0.5–4.9) | 0.221 |